(Q38995020)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

review article

1 reference

title

Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Simone Ferrero

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

Umberto Leone Roberti Maggiore

26 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Valerio Gaetano Vellone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Giorgia Mangili

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

10

Massimo Candiani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Carolina Scala

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Francesca Pella

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Micaela Petrone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Emanuela Rabaiotti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Raffaella Cioffi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

language of work or name

English

0 references

publication date

1 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

26 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

1405-1412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

cites work

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Rethinking ovarian cancer: recommendations for improving outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Sorafenib for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

The potential of sunitinib as a therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

An overview of early investigational therapies for chemoresistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Mechanisms of membrane transport of folates into cells and across epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Role of folate receptor genes in reproduction and related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Overexpression of folate binding protein in ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Role of farletuzumab in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Folate receptor alpha as a tumor target in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Functional folate receptor alpha is elevated in the blood of ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

Targeting folate receptor alpha for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1254616

10.1080/13543784.2016.1254616

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27797594%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference